Heart Drug SCANDAL: Risks Hidden For Decades

Medical professionals in an operating room monitoring a patient

A heart drug millions swallow every day after a heart attack may be doing far less than promised for many – and for a slice of patients, it may even tilt the odds the wrong way.

Story Snapshot

New, revascularization-era trials show beta blockers give no clear survival benefit after uncomplicated heart attacks with normal pumping function.
For decades, guidelines told doctors to put almost every heart attack survivor on these drugs for years – that blanket rule no longer fits the evidence.
Emerging data hint at possible harm or at least needless side effects in some lower-risk groups, especially women with preserved heart function.

How beta blockers became untouchable after a heart attack

Cardiologists in the 1970s and 1980s saw something dramatic: in an era before rapid artery-opening procedures and modern statins, beta blockers clearly helped heart attack survivors live longer.^[3] Those early trials shaped American Heart Association and American College of Cardiology guidance that told doctors to start beta blockers in virtually all post–heart attack patients and often keep them going indefinitely.^[3] The message to patients was simple: you had a heart attack, you go home with a beta blocker, period.

That doctrine hardened into habit. Hospitals measured quality by how reliably they sent heart attack patients home on beta blockers. Doctors internalized “never stop a cardiology drug that once showed benefit,” even while the entire landscape of heart care changed. Today, most patients get rapid angioplasty to open blocked arteries, high-intensity statins, aspirin, and powerful blood pressure and diabetes control. The patients look nothing like the populations that established the original beta blocker benefit.^[2]^[5]

What the new trials in modern patients actually show

Recent high-quality trials finally asked the obvious question: in the modern era, do beta blockers still improve outcomes in heart attack survivors whose heart pumping function is normal or near normal? The REDUCE-AMI trial randomized such patients and found no reduction in death or new heart attack with long-term beta blocker therapy compared with no beta blocker.^[5] The primary outcome occurred in 7.9 percent of the beta blocker group and 8.3 percent of the no–beta blocker group, statistically indistinguishable.^[3]^[5]

Meta-analyses pooling contemporary trials tell the same story. A Bayesian analysis of over 24,000 patients with prior heart attack and preserved ejection fraction found no statistically credible reduction in all-cause death or major cardiovascular events with beta blockers.^[1] Another review of nearly 20,000 patients showed no significant difference in cardiovascular death, recurrent heart attack, heart failure, or unplanned procedures between beta blocker and control groups when ejection fraction was preserved.^[4] In plain English: for many modern, lower-risk survivors, beta blockers add pills, not protection.

Where benefit still exists – and where concerns are rising

These findings do not erase the value of beta blockers everywhere. Patients whose hearts are weakened – ejection fraction below about 40 to 50 percent – or who have clear heart failure still gain meaningful benefit in mortality and hospitalizations.^[2]^[6] Subgroup analyses and updated meta-analyses suggest the remaining signal of benefit clusters in those with mildly reduced function, not in those whose hearts pump normally.^[6]

In a meta-analysis involving 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. ⁣
⁣
Read the full trial results and Research Summary at … pic.twitter.com/5gskbgBUGT

— NEJM (@nejm99mp) May 25, 2026

The more unsettling twist comes from trials like REBOOT, which examined uncomplicated heart attack survivors, most with preserved function, discharged on beta blockers. Investigators reported no overall benefit and flagged that women in particular might fare worse on beta blockers after uncomplicated heart attack. That sex signal is not definitive yet, but it aligns with a broader pattern in medicine where women often bear more side effects and less benefit from legacy, one-size-fits-all protocols built on male-dominated trial populations.

Guidelines catching up

Guideline writers have started to blink. Contemporary summaries from major cardiology societies now acknowledge that continuing beta blockers beyond the first year after an uncomplicated heart attack does not improve outcomes in patients without heart failure or reduced ejection fraction.^[4] Observational work in such patients shows no survival advantage to staying on beta blockers after one year, undercutting the old practice of lifelong therapy out of inertia or fear.

What patients and families should ask now

Patients who survived an uncomplicated heart attack with normal heart function and remain on beta blockers for years have every reason to ask their doctors hard questions. The evidence now shows little to no outcome gain for many in that group, and some women may even face worse results.^[5] A thoughtful discussion about blood pressure, symptoms, side effects, and heart function can often justify tapering or stopping, instead of clinging to an outdated blanket rule that newer trials no longer support.